Released May 14, 2014, after the close
10-Q filed May 15, 2014, 45 days after period end · 0001019687-14-001956
Q1 2014 · 10-Q
Revenue$6.42M$6.42M +4.9% vs Q1 2013−2.4% vs Q4 2013
Net Income-$649.00K-$649.00K N/M vs Q1 2013N/M vs Q4 2013
EPS Diluted-$0.01-$0.01 N/M vs Q1 2013no prior Q4 2013 on file
Operating Income-$654,000N/M
Operating Cash Flow-$453,000N/M
Free Cash Flowderived-$775,000N/M
Margins · derived
Operating margin-10.2%−4.2 pt vs Q1 2013
Net margin-10.1%−4.1 pt vs Q1 2013
What the release said
The release
Same quarter
| Metric | Q1 2014 | Q1 2013 | Q1 2012 | Q1 2011 |
|---|---|---|---|---|
| Revenue | $6.42M | $6.12M | $6.07M | $6.00M |
| Net Income | -$649.00K | -$369.00K | -$1.05M | -$559.00K |
| EPS Diluted | -$0.01 | -$0.01 | -$0.02 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR